Collegium Pharmaceutical stock performance snapshot

Collegium Pharmaceutical (COLL) has drawn investor attention after recent trading, with the share price at $37.27 and short term returns under pressure, including a 10.4% decline over the past week.

The stock has also seen a 21.7% decline over the past month and 20.8% over the past 3 months, even as the company reports annual revenue of $780.567m and net income of $62.87m.

While the recent 1 month and 3 month share price returns have been weak, Collegium Pharmaceutical’s 1 year total shareholder return of 25.66% and 3 year total shareholder return of 55.62% point to earlier, stronger momentum that has since faded.

If this volatility has you thinking about diversification, it could be a good moment to scan our screener of 32 healthcare AI stocks as a starting point for other ideas in the broader healthcare space.

With Collegium Pharmaceutical trading at $37.27, recent weakness sits alongside annual revenue of $780.567m, net income of $62.87m and a value score of 6. Is this a potential opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 30.6% Undervalued

Collegium Pharmaceutical's most followed narrative pegs fair value at $53.67 versus the last close of $37.27, a wide gap that hinges on a detailed earnings and margin roadmap.

The company's differentiated pain portfolio, notably with products featuring proprietary abuse-deterrent and extended-release technologies (e.g., Xtampza ER's DETERx platform), is supported by industry and regulatory trends that increasingly favor safer opioid options, likely enhancing market share, pricing power, and sustaining net margins as regulatory emphasis on abuse deterrence grows.

Want to see what kind of revenue mix, margin path, and future P/E multiple this narrative is baking in? The fair value hinges on a tight set of earnings targets and share count assumptions that go well beyond a simple top line story.

Result: Fair Value of $53.67 (UNDERVALUED)

However, this depends on key risks, including potential generic competition for core pain brands from 2027 and pressure on pricing or reimbursement for opioid based therapies.

Next Steps

Given the mix of optimism and concern in this story, it is worth checking the data yourself soon and weighing up 4 key rewards and 2 important warning signs before deciding what it means for you.

Looking for more investment ideas?

If this story has you rethinking your watchlist, do not stop at one company. Use targeted screens to hunt for opportunities that actually fit your style.

• Focus on quality by scanning companies our tools flag as 46 high quality undervalued stocks that pair stronger fundamentals with prices the market may be overlooking.
• Prioritise resilience by checking out 63 resilient stocks with low risk scores that our models assess with steadier risk profiles for investors who want fewer surprises.
• Spot potential early stage standouts through our screener containing 23 high quality undiscovered gems and see which names have solid underpinnings before they hit everyone’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.